TG Therapeutics, Inc. (TGTX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Morrisville, NY, United States. The current CEO is Michael S. Weiss.
TGTX has IPO date of 2010-05-03, 352 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $5.52B.
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes novel treatments targeting B-cell malignancies and autoimmune diseases. The company's lead products include Ublituximab, a monoclonal antibody for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple sclerosis, and Umbralisib, an oral PI3K-delta and CK1-epsilon inhibitor for various lymphomas and leukemia. The pipeline also includes clinical and preclinical candidates such as Cosibelimab (a PD-L1 inhibitor), TG-1701 (a BTK inhibitor), TG-1801 (a bispecific CD47/CD19 antibody), and programs targeting BET, IRAK-4, and GITR. Founded in 1993 and headquartered in New York, TG Therapeutics maintains strategic collaborations and partnerships with leading global pharmaceutical and biotechnology organizations to advance its therapeutic development programs.
